Samantha K. Tucker

Samantha K. Tucker

Auto-generated profile, based on publicly available information

Samantha K. Tucker

University of Glasgow

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in bioRxiv
Verified
Preprint
Open access
MFMaxwell J. Farrell
Maxwell J. Farrell
STSamantha K. Tucker
Samantha K. Tucker
NMNardus Mollentze
Nardus Mollentze
DSDaniel Streicker
Daniel Streicker
A common explanation for bats being a conspicuous source of zoonotic viruses is their purported ability to coexist with viruses without suffering overt disease. This belief has catalyzed the discovery of unique features of bat immune systems which may have translational value as broad-spectrum antivirals, particularly if they evolved as a byproduct of bats’ unique life history rather than through conventional co-evolutionary processes. Surprisingly, whether bats compared to other host groups suffer less disease from co-evolved viruses or from viruses generally has not been formally assessed. Here, synthesizing eighty-six years of experimental infections, involving 54 viruses, 85 host species, and over 5,600 animals, we document disease in bats following inoculation by taxonomically diverse viruses, including ones that are relatively benign in humans. The occurrence of overt disease, the likelihood of mortality, and the severity of disease in bats were indistinguishable from those experienced by rodents, another group associated with many zoonotic viruses. These patterns were consistent when considering only bat-associated viruses inoculated into bats and rodent-associated viruses inoculated into rodents and among inoculations which lacked shared co-evolutionary history. Instead, disease outcomes following infection were shaped by experimental design, viral host range, and evolutionary context. Unexceptional disease in bats from novel or co-evolved infections suggests that order-level host life history traits such as flight have inconsistent consequences for antiviral immunity and highlights the need to evaluate the functions of unique features of bat immunity in vivo. These results do not exclude the possibility of developing broader-acting or more potent antivirals from bat immune systems, but do not support the idea that bats will be an unusually rich source of future biomedical breakthroughs.

19 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
DMDavid Mark
David Mark
NONicky O’boyle
Nicky O’boyle
KWKabo Ronald Wale
Kabo Ronald Wale
STSamantha K Tucker
Samantha K Tucker
RMRebecca E McHugh
Rebecca E McHugh
ARAndrew J Roe
Andrew J Roe
Gram-negative pathogens pose a significant threat due to their propensity for causing various infections, often coupled with formidable resistance to conventional antibiotic treatments. In light of this challenge, the development of antivirulence (AV) compounds emerges as a promising alternative strategy, aiming to disrupt key virulence mechanisms rather than directly targeting bacterial viability. One such compound, aurodox, derived from Streptomyces goldiniensis , has exhibited promising AV properties in our prior studies. Specifically, aurodox caused a marked downregulation in the expression and function of the E. coli type 3 secretion system (T3SS), a needle-like injectosome structure which is deployed to translocate effector proteins from the cytoplasm to the host target cells. However, the broader spectrum of aurodox’s efficacy against T3SS across diverse pathogens remained unanswered, prompting the focus of this work. Using quantitative real-time PCR, we show that aurodox exerts inhibitory effects on selected T3SS in various pathogens, including Salmonella typhimurium, Yersinia pseudotuberculosis , and Vibrio parahaemolyticus . However, aurodox was not a universal blocker of all secretion systems, showing selectivity in its mode-of-action, even within a single strain. This finding was verified using transcriptomics which demonstrated that aurodox selectively blocks the expression of the Salmonella typhimurium SPI-2 type T3SS whilst other pathogenicity islands, including the SPI-1 system were not inhibited. To delve deeper into the mechanisms governing aurodox’s efficacy against these pathogens, we analysed transcriptomic datasets from both E. coli and S. Typhimurium treated with aurodox. By identifying orthologous genes exhibiting differential expression in response to aurodox treatment across these pathogens, our study sheds light on the potential mechanisms underlying the action of this rediscovered antibiotic.

1 June 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
STS. Tucker
S. Tucker
RLRaya Leibowitz
Raya Leibowitz
4734 Background: Reports of intermittent androgen deprivation (IAD) for PC show equivalence and potential superiority to continuous AD. Failure of IAD results in androgen independent PC (AIPC) for which docetaxel (D) is standard. Given the volume of systemic disease and occult AIPC cells in MPC we have augmented AD with D chemotherapy since 1997 in LAPC and MPC. We report long-term results using a single cycle of CHT for LAPC and MPC. Methods: We have prospectively treated 41 men with PC with CHT. CHT consisted of Triple Androgen Blockade (an LH-RH agonist and antiandrogen or adrenolytic and finasteride 5 MG QD) plus weekly D based chemotherapy. Finasteride 5 MG QD maintenance (FM) was continued in all men when CHT was completed. D was dosed at 25 mg/M2 days 1, 8, and 15 of a 28 day cycle for 4–5 cycles. Estramustine was given as 280 MG TID day of D and day after only. Carboplatin 200 mg weekly was given to 65% of patients. Follow-up QOL has been measured with a validated symptom-based scale for pen-based computers. Results: Median age was 64, mean baseline PSA (bPSA) was 262 ng/mL (range 1–5606); median PSA was 23 ng/mL. Median Gleason score (GS) was 9 (range 6–10). Mean baseline testosterone (T) was 436 ng/dL. Median duration of CHT was 12.6 months. A mean of 13.7 doses of weekly chemotherapy was given. At a median follow-up of 42 months (range 11–76) mean PSA is 11.5 ng/mL. Mean current T is 398 ng/dl. A second cycle of CHT has been initiated in 10/41 men (8 of whom presented with MPC). 3 men with MPC have died from AIPC. Disease specific survival is 92.6%. Detailed QOL data will be presented in full. Conclusions: A single 13 month cycle of CHT provides excellent long-term control and management of poor prognosis LAPC and MPC. D based CHT should be explored further for men with newly diagnosed LAPC or MPC and compared with AD alone. Measurement of time to androgen independence is the appropriate surrogate to measure in this setting.

29 October 2026 in PLOS Biology
Verified
Journal Article
Open access
PDF file
MFMaxwell J. Farrell
Maxwell J. Farrell
STSamantha K. Tucker
Samantha K. Tucker
NMNardus Mollentze
Nardus Mollentze
DSDaniel Streicker
Daniel Streicker
A common explanation for bats being a conspicuous source of zoonotic viruses is their purported ability to coexist with viruses without suffering overt disease. Widespread acceptance of the idea that bats have unusual antiviral traits has catalyzed the discovery of unique features of bat immune systems which may have translational value as broad-spectrum antivirals, particularly if they evolved as a byproduct of bats’ unique life history rather than through conventional co-evolutionary processes. Surprisingly, whether bats compared to other host groups suffer less disease from co-evolved viruses or from viruses generally has not been formally assessed. Here, synthesizing 86 years of experimental infections, involving 54 viruses, 85 host species, and over 5,600 animals, we document disease in bats following inoculation by taxonomically diverse viruses, including ones that are relatively benign in humans. The occurrence of overt disease, the likelihood of mortality, and the severity of disease in bats were indistinguishable from those experienced by rodents, another group associated with many zoonotic viruses. These patterns were consistent when considering only bat-associated viruses inoculated into bats and rodent-associated viruses inoculated into rodents and among inoculations which lacked shared co-evolutionary history. Instead, disease outcomes following infection were shaped by experimental design, viral host range, and evolutionary context. Unexceptional disease in bats from novel or co-evolved infections suggests that order-level host life history traits such as flight have inconsistent consequences for antiviral immunity and highlights the need to evaluate the functional properties of putatively unique features of bat immunity in vivo. While these results do not exclude the possibility of developing broader-acting or more potent antivirals from bat immune systems or diminish the potential value of mechanistic insights into bat immunity, they suggest that bat immune systems were shaped by conventional co-evolutionary processes rather than through unique circumstances that endow exceptional antiviral defenses.

11 August 2026 in Microbiology
Verified
Journal Article
Open access
ABAinsley D.M. Beaton
Ainsley D.M. Beaton
JCJames T. Croxford
James T. Croxford
AAAlejandra C. Díaz de Aguinaga
Alejandra C. Díaz de Aguinaga
EHEmily Horsburgh
Emily Horsburgh
DMDavid R. Mark
David R. Mark
RMRebecca E. McHugh
Rebecca E. McHugh
Graphical Phylogenetic tree highlighting members of the kingdom Animalia with characterized Streptomyces interactions. Images have been coloured using stereoimages of Streptomyces colonies.